This $135,594 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to The Leland Stanford Junior University supports research to develop novel pharmacological approaches for rewiring oncogenic gene expression and activating apoptosis in cancer cells. The objectives are to: 1) Develop small molecule chemical inducers of proximity (CIPs) that can kill aggressive leukemias driven by translocations of the mixed-lineage-leukemia (MLL) gene, and 2) Discover the core molecular principles underlying how CIPs can rewire transcription factors to activate pro-apoptotic genes. This research aims to yield new targeted therapies for MLL-rearranged leukemias and generate important structural insights to inform the rational design of small molecules for rewiring oncogenic gene expression. The award period is from April 1, 2025 to March 31, 2027.
Generated 3/25/25, 3:29 AM